II. Indications

  1. Massive Hemorrhage (e.g. Trauma, cardiac surgery, Postpartum Hemorrhage)
    1. Alternative to Cryoprecipitate
    2. Trauma or Gastrointestinal Bleeding
      1. Transfuse Fibrinogen Concentrate (or Cryoprecipitate) if Fibrinogen <150 mg/dl
    3. Postpartum Hemorrhage
      1. Transfuse Fibrinogen Concentrate (or Cryoprecipitate) if Fibrinogen <200 mg/dl

III. Efficacy: Massive Hemorrhage

  1. Noninferior to cryprecipitate in cardiac surgery related bleeding
    1. Farkouh (2019) JAMA 322(20): 1966-76 [PubMed]
  2. In contrast to Cryoprecipitate, Fibrinogen has several advantages
    1. Consistent dosing (variable with Cryoprecipitate)
    2. Rapidly reconstituted (no thawing needed)
    3. Longer shelf life (24 hours instead of 6 hours)
    4. No major transfusion adverse effects

IV. References

  1. Petrosoniak and Swaminathan in Swadron (January, 2023) EM:RAP

Images: Related links to external sites (from Bing)

Related Studies

Ontology: fibrinogen concentrate (human) (C2587184)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
SnomedCT 312063004, 418326009
Spanish fibrinógeno humano (sustancia), fibrinógeno humano (calificador), fibrinógeno humano, fibrinógeno humano (producto)
English Fibrinogen, Fibrinogen Human, FIBRINOGEN, Fibrinogen Concentrate (Human), Fibrinogen Human Plasma-Derived, FIBRINOGEN HUMAN, fibrinogen concentrate (human), fibrinogen, human, Human fibrinogen, Human fibrinogen (product), Human fibrinogen (qualifier value), Human fibrinogen (substance)